Youdim Pharmaceuticals is developing a novel oral drug, MT-031, for the treatment of the symptoms related to Alzheimer’s Disease. MT-031 structure combines Rivastigmine (Exelon) and Rasagiline (Azilect) moieties and it has the beneficial properties of both and more. The molecule and its indications are protected by a recently granted US and EP patents.

Alzheimer’s disease (AD) is a subtype of dementia and is an irreversible, neurodegenerative brain disease of the elderly. AD is characterized by the death of brain cells, which leads to a progressive decline in memory and cognitive abilities including thinking, language, and learning capacity (National Institute on Aging, 2019). AD is the most common cause of dementia in people ages 60 years and older, and accounts for approximately 75% of the total dementia cases worldwide. In 2018, GlobalData estimated that the global AD market reached $2.2 billion across the eight major markets (China, US, Japan, Germany, Italy, France, UK and Spain). By the end of the forecast period in 2028, sales across these markets will reach $12.9 billion, increasing at a Compound Annual Growth Rate (CAGR) of 19.3% over the 10-year forecast period.

The AD market is unique in its level of unmet clinical and environmental need. The current market consists of four main brands—Eisai/Pfizer’s Aricept (Donepezil hydrochloride), Novartis’ Exelon (Rivastigmine), Janssen’s Razadyne (Galantamine), and Allergan/Lundbeck/Merz’s Namenda (Memantine hydrochloride)—all of which can confer modest symptomatic benefits.

Is a multifunctional drug designed for the treatment of dementia and Alzheimer Disease. Its structure combines Rivastigmine (Exelon) and Rasagiline (Azilect) moieties. It works as a dual Acetylcholinesterase (AChE) and Butyrylcholinesterase (BuChE) inhibitor as well a selective irreversible inhibition of MAO-A.

Our findings demonstrated that MT-031 has the following attributes:

• Strategic collaboration with Pharmaceutical companies
• Investment for IND

www.Exegiline.com